Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective64
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting29
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation22
Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review17
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants15
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts13
Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam9
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report9
It’s about time: The association between abacavir and cardiovascular disease9
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway9
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity9
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud7
Pharmacokinetic and mass balance characterization of [ 14 C] RAY1216, a SARS-CoV-2 M pro inhibitor6
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review6
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines6
A favipiravir-induced angioedema and urticaria in a COVID-19 patient6
Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study5
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database5
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort5
Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV5
The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis5
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study5
Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case–control study from Uganda and South Africa5
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach5
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine5
Lipid and glucose abnormalities and associated factors among children living with HIV in Asia5
0.69716787338257